Do you need more information
Help promote effective infection control through reliable screening* of extended-spectrum beta lactamase-producing enterobacteriaceae (ESBL) with chromID™ ESBL selective chromogenic media.
*ESBL production must be confirmed
Do you need more information
Today’s healthcare environment is more complex and challenging than ever before, with multi-drug resistant organisms (MDRO) and related risk of healthcare associated infection (HAI) outbreaks among the most critical concerns. Many healthcare associated infections are caused by enterobacteriaceae. When these bacteria produce extended-spectrum β-lactamase (ESBL) enzymes, they become resistant to our most common antibiotics, and are particularly likely to lead to morbidity and mortality from bloodstream infections. ESBL-producing enterobacteriaceae are recognized worldwide as nosocomial pathogens of major importance, listed as a “serious threat” by the Centers for Disease Control1. Rapid, reliable screening of ESBL is essential to improved patient care, infection control and outbreak management.
1) Antibiotic Resistance Threats in the United States, CDC 2013
CHROMID™ ESBL is part of the bioMérieux SMART range of media, developed specifically to address the challenges of MDRO and HAI. CHROMID™ ESBL is based on an agar with a patented mixture of antibiotics designed specifically to enable the selective growth of ESBL-producing enterobacteriaceae* and CHROMogenic substrates for the direct identification of the most frequently encountered ESBL-producing enterobacteriaceae. CHROMID™ ESBL provides results in 18-24 hours, enabling timely delivery of results to support effective infection control measures for better patient outcomes and cost-containment thanks to faster responses.
CHROMID™ ESBL provides rapid, easy-to-read results
* ESBL production must be confirmed by additional tests
CHROMID™ ESBL provides high sensitivity thanks to the inclusion of the antibiotic Cefpodoxime, the marker of choice for this resistance mechanism. Time-to-results is also shortened by a high level of specificity and the reduced number of confirmation tests needed. After optimal incubation of 18 hours, you’ll be confident in the reliability of easy-to-read results with the specific coloration enhanced by CHROMogenic media:
Need to know if CHROMID™ ESBL and another product are compatible? You can easily access this information through a validated Certificate of Compatibility which clearly shows product compatibility with complementary instruments and reagents.
CHROMID™ ESBL | ||
---|---|---|
chromid_esbl.pngShow in media library: |
43481 | 20 x 90 mm |
Assessment of prevalence and changing epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae fecal carriers using a chromogenic medium
Paniagua R et al. Diagnostic Microbiology And Infectious Disease 2010;67:376-379
Performance of chromID ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum ß-lactamases
Réglier-Poupet H et al.Journal Of Medical Microbiology, 2008;57:310-315
ECCMID 2012 / London (United Kingdom)
A multi-center evaluation of 3 selective screening agars for the detection of extended-spectrum ß-lactamases
Floré K et al. ECCMID 2009 / Helsinki (Finland)
Evaluation of a chromogenic bioMérieux chromID ESBL medium for screening and presumptive identification of extended-spectrum ß-lactamase-producing Enterobacteriaceae from surveillance cultures
Sánchez-Carrillo C et al.
Comparison of the chromID™ ESBL medium and MacConkey agar supplemented with ceftazdime (5mg/l) for the detection of extended-spectrum beta-lactamase producing Enterobacteriaceae from rectal swabs in hospitals patients
Nonhoff C et al.